Company Overview and News
Leagold should produce 420,000-475,000 toz gold at an AISC around $930/toz in 2018, however, its production should grow to the 700,000 toz level by 2020.
OCANF SCGLF AUY YRI EDVVF EDVMF SCGLY EVR GLE GG HTXFF EDV
Below is a list of 10 quality gold producers. I have selected them as the best risk/reward leveraged gold stocks. All of these should outperform the price of gold if it rises. In fact, I expect all of these stocks to double in value if gold reaches $1,600. These are the stocks that you want to own if you are looking for high returns if gold prices start trending. Also, if you are looking for a way to hedge against a market crash, then these stocks offer a potential hedge.
NGDAF ARNGF NGD TGD MUX.RTWI HUMRF DGC EDVVF PMNXF GCM.WT.A PRU MUX AR HTXFF HUM EDV RPM NGD ALO MUX TPWRF WDO EDVMF RPMGD DRGDF RPMGF PRU TPRFF GCM TMM EVR WDOFF
TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- BRIO GOLD INC. (TSX:BRIO) (“BRIO GOLD” or the “Company”) is pleased to announce the receipt of the clearance decision from the Comisión Federal de Competencia Económica (“COFECE”) with respect to Leagold Mining Corporation’s acquisition of Brio Gold. COFECE approval was the final government agency approval required before completing the acquisition, which is anticipated to occur on or around May 24, 2018.
TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- BRIO GOLD INC. (TSX:BRIO) (“BRIO GOLD” or the “Company”) is pleased to announce that it has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving its previously announced plan of arrangement (the “Arrangement”) with Leagold Mining Corporation (“Leagold”), whereby Leagold will acquire all of the issued and outstanding shares of Brio Gold pursuant to an arrangement agreement dated February 15, 2018.
TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- BRIO GOLD INC. (“BRIO GOLD” or the “Company”) (TSX:BRIO) herein announces the voting results from the Company's Special Meeting held on April 12, 2018 (the "Meeting"). At the Meeting, shareholders of the Company were asked to consider and, if deemed advisable, to approve a special resolution (the “Arrangement Resolution”) authorizing the proposed plan of arrangement (the “Arrangement”) of Brio Gold under section 182 of the Business Corporations Act (Ontario), whereby Leagold Mining Corporation will acquire all of the issued and outstanding shares of Brio Gold pursuant to an arrangement agreement dated February 15, 2018.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET